Metabolic manipulation of host cells by intracellular pathogens is currently recognized to play an important role in the pathology of infection. Nevertheless, little information is available regarding mitochondrial energy metabolism in Leishmania infected macrophages. Here, we demonstrate that during L. infantum infection, macrophages switch from an early glycolytic metabolism to an oxidative phosphorylation, and this metabolic deviation requires SIRT1 and LKB1/AMPK. SIRT1 or LBK1 deficient macrophages infected with L. infantum failed to activate AMPK and up-regulate its targets such as Slc2a4 and Ppargc1a, which are essential for parasite growth. As a result, impairment of metabolic switch caused by SIRT1 or AMPK deficiency reduces parasite load in vitro and in vivo. Overall, our work demonstrates the importance of SIRT1 and AMPK energetic sensors for parasite intracellular survival and proliferation, highlighting the modulation of these proteins as potential therapeutic targets for the treatment of leishmaniasis. Leishmania infantum, a causative agent of visceral leishmaniasis, is able to infect host macrophages and modulate a myriad of signalling pathways that contributes to the disease outcome. In order to survive, L. infantum must compete with the host for the same metabolic resources, however scarce attention has been dedicated to clarify the potential interference of the parasite with the host metabolic pathways and its impact for the infection outcome. We analysed the macrophage metabolic alterations induced by L. infantum focusing on host energetic players exploited by the parasite. We describe that L. infantum induced a metabolic switch from an early aerobic glycolytic environment to a later mitochondrial metabolism. In this process, L. infantum modulates important energetic sensors of the host, such as the SIRT1-LKB1-AMPK axis. This triad is important for the recovery of the host energetic status and also for the parasite survival. With this work, we demonstrate that the host SIRT1-LKB1-AMPK axis has a crucial impact on the parasite survival in vitro and in vivo.
Membrane-anchored ephrinB2 and its receptor EphB4 are involved in the formation of blood and lymphatic vessels in normal and pathologic conditions. Eph/ephrin activation requires cell-cell interactions and leads to bidirectional signaling pathways in both ligand- and receptor-expressing cells. To investigate the functional consequences of blocking ephrinB2 activity, 2 highly specific human single-chain Fv (scFv) Ab fragments against ephrinB2 were generated and characterized. Both Ab fragments suppressed endothelial cell migration and tube formation in vitro in response to VEGF and provoked abnormal cell motility and actin cytoskeleton alterations in isolated endothelial cells. As only one of them (B11) competed for binding of ephrinB2 to EphB4, these data suggest an EphB-receptor–independent blocking mechanism. Anti-ephrinB2 therapy reduced VEGF-induced neovascularization in a mouse Matrigel plug assay. Moreover, systemic administration of ephrinB2-blocking Abs caused a drastic reduction in the number of blood and lymphatic vessels in xenografted mice and a concomitant reduction in tumor growth. Our results show for the first time that specific Ab-based ephrinB2 targeting may represent an effective therapeutic strategy to be used as an alternative or in combination with existing antiangiogenic drugs for treating patients with cancer and other angiogenesis-related diseases.
Uncoupling protein 2 (UCP2) is a mitochondrial transporter that has been shown to lower the production of reactive oxygen species (ROS). Intracellular pathogens such as Leishmania upregulate UCP2 and thereby suppress ROS production in infected host tissues, allowing the multiplication of parasites within murine phagocytes. This makes host UCP2 and ROS production potential targets in the development of antileishmanial therapies. Here we explore how UCP2 affects the outcome of cutaneous leishmaniosis (CL) and visceral leishmaniosis (VL) in wild-type (WT) C57BL/6 mice and in C57BL/6 mice lacking the UCP2 gene (UCP2KO). To investigate the effects of host UCP2 deficiency on Leishmania infection, we evaluated parasite loads and cytokine production in target organs. Parasite loads were significantly lower in infected UCP2KO mice than in infected WT mice. We also found that UCP2KO mice produced significantly more interferon-γ (IFN-γ), IL-17 and IL-13 than WT mice (P<0.05), suggesting that UCP2KO mice are resistant to Leishmania infection. In this way, UCP2KO mice were better able than their WT counterparts to overcome L. major and L. infantum infections. These findings suggest that upregulating host ROS levels, perhaps by inhibiting UPC2, may be an effective approach to preventing leishmaniosis. The leishmaniases comprise a group of diseases caused by infection by several species of intracellular protozoan parasites of the genus Leishmania, which are transmitted by the bite of an infected sandfly. The leishmaniases represent a global public health problem, affecting an estimated 12 million people around the world and ranging from self-healing skin lesions to potentially fatal systemic infections. Here, we use mouse models of CL and VL to investigate the effect of a host gene called UCP2. Uncoupling protein 2 (UCP2) is a mitochondrial carrier expressed in a wide variety of tissues, including white adipose tissue, skeletal muscle and the immune system. Intracellular pathogens such as Leishmania upregulate UCP2 and may weaken the immune system. Consequently, parasites survive and multiply within mouse macrophages. We demonstrate here that mice lacking the UCP2 gene are better able than WT mice to control both CL and VL. Infection was analyzed in vivo by measurement of footpad swelling, quantification of parasite load and assays for the production of cytokines and Leishmania-specific antibodies. These findings could have important implications in designing an effective approach to preventing leishmaniosis.